A new blood test, named the Galleri liquid biopsy, has been introduced to the market, offering the potential to detect early signs of cancer. Priced at $949, the test claims to screen for over 50 types of cancers by identifying a common cancer signal present in DNA fragments released by tumors into the bloodstream. Since its launch in June 2021, Grail, the company behind Galleri and a subsidiary of gene-sequencing firm Illumina, has reported sales of more than 130,000 prescription-only tests. However, the medical community appears divided on the test’s current utility, with some expressing excitement about its potential, while others remain cautious about its immediate adoption.
This $1,000 Test Finds Signs of Cancer in Your Blood (The Wall Street Journal)
0